AEON Biopharma Says FDA Indicated Prior Head-To-Head Studies Vs. Botox Can Be Submitted As Supportive Evidence For ABP-450 Biosimilar

Loading news article.

AEON Biopharma Says FDA Indicated Prior Head-To-Head Studies Vs. Botox Can Be Submitted As Supportive Evidence For ABP-450 Biosimilar | WAPE

Article summary